Bladder Cancer

Oncology / Haematology

A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4

Endothelial Cancer

Oncology / Haematology

Phase III double-blind randomised placebo controlled trial of Atezolizumab in combination with Paclitaxel and Carboplatin in women with advanced/recurrent endometrial cancer.

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4

Ovarian Cancer

Oncology / Haematology

A Phase II randomised trial comparing immune priming by low dose oral cyclophosphamide plus olaparib versus priming by olaparib alone, prior to combination therapy with olaparib plus durvalumab, versus single agent olaparib alone, in asymptomatic platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancers with homologous recombination repair defects

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4

Lung Cancer

Oncology / Haematology

A Phase 3, randomized, double-blinded, placebo-controlled study of Tiragolumab, an anti-Tigit-antibody, in combination with atezolizumab compared with placebo in combination with atezolizumab in patients with previously untreated locally advanced unresectable or metastatic PD-L1-selected Non-small cell lung cancer

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4

Breast Cancer

Oncology / Haematology

A Phase III Randomised, double blind, placebo controlled, multicentre study evaluating the efficacy and safety of GDC-9545 combined with Palbociclib in women with estrogen receptor positive, HER2-negative locally advanced or metastatic breast cancer.

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4

Breast Cancer

Oncology / Haematology

A randomized phase II trial evaluating the efficacy of a nivolumab monotherapy lead in or commencement of nivolumab with paclitaxel and carboplatin as neo-adjuvant therapy in early stage triple negative breast cancers

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4

Breast Cancer

Oncology / Haematology

A Phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (DS-8201a), an anti-HER2-antibody drug conjugate, versus treatment of investigator’s choice for HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with T-DM1

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4

Breast Cancer

Oncology / Haematology

A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer.

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4

Breast Cancer

Oncology / Haematology

A Randomized, Double-Blind, Phase III Study of embrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast Cancer

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4